Skip to main content
. 2014 Jul 31;111(6):1080–1088. doi: 10.1038/bjc.2014.423

Figure 2.

Figure 2

The effects of donor KIR2DS1 positivity on the relapse of recipients with HLA-C2 ligand. The cumulative incidence estimate for the probability of molecular (A) and haematologic (B) relapse in CML patients who were HLA-C2 positive (HLA-C1C2 or HLA-C2C2) accepting donors with KIR2DS1 positivity, compared with those patients who were HLA-C2 negative (HLA-C1C1) accepting donors with KIR2DS1 positivity or negativity after haploidentical T-cell-replete transplantation.